Loading clinical trials...
Loading clinical trials...
A 6-Month, Double-Blind, Placebo-Controlled Pilot Study of High-Dose Resveratrol in Patients With Stable Ischemic Heart Disease
Conditions
Interventions
High-dose resveratrol 500 mg/day
Placebo
Locations
1
Russia
Center for New Medical Technologies
Novosibirsk, Russia
Start Date
February 1, 2024
Primary Completion Date
January 20, 2025
Completion Date
February 10, 2025
Last Updated
April 23, 2025
Lead Sponsor
S.LAB (SOLOWAYS)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions